Mylan gets US FDA nod for metformin and glipizide tabs

Mylan Laboratories Inc. has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glipizide and Metformin Hydrochloride tablets in 2.5-mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths. Glipizide and Metformin Hydrochloride tablets are the generic version of Bristol Myers Squibb's Metaglip tablets. Glipizide and Metformin Hydrochloride Tablets had US sales of approximately $29 million for the same strengths for the 12-month period ended Dec. 31, 2006, according to IMS Health. Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries Mylan Pharmaceuticals Inc.